Title: Valproic acid disrupts the oscillatory expression of core circadian rhythm transcription factors.

Authors: Griggs, Chanel A; Malm, Scott W; Jaime-Frias, Rosa; Smith, Catharine L

Published In Toxicol Appl Pharmacol, (2018 Jan 15)

Abstract: Valproic acid (VPA) is a well-established therapeutic used in treatment of seizure and mood disorders as well as migraines and a known hepatotoxicant. About 50% of VPA users experience metabolic disruptions, including weight gain, hyperlipidemia, and hyperinsulinemia, among others. Several of these metabolic abnormalities are similar to the effects of circadian rhythm disruption. In the current study, we examine the effect of VPA exposure on the expression of core circadian transcription factors that drive the circadian clock via a transcription-translation feedback loop. In cells with an unsynchronized clock, VPA simultaneously upregulated the expression of genes encoding core circadian transcription factors that regulate the positive and negative limbs of the feedback loop. Using low dose glucocorticoid, we synchronized cultured fibroblast cells to a circadian oscillatory pattern. Whether VPA was added at the time of synchronization or 12h later at CT12, we found that VPA disrupted the oscillatory expression of multiple genes encoding essential transcription factors that regulate circadian rhythm. Therefore, we conclude that VPA has a potent effect on the circadian rhythm transcription-translation feedback loop that may be linked to negative VPA side effects in humans. Furthermore, our study suggests potential chronopharmacology implications of VPA usage.

PubMed ID: 29229235

MeSH Terms: Animals; Anticonvulsants/toxicity*; Cell Line, Tumor; Circadian Rhythm/drug effects*; Circadian Rhythm/physiology; Dose-Response Relationship, Drug; Gene Expression; Mice; NIH 3T3 Cells; Transcription Factors/biosynthesis*; Transcription Factors/genetics; Transcriptional Activation/drug effects*; Transcriptional Activation/physiology; Valproic Acid/toxicity*